MenFive Meningococcal (A, C, Y, W, X) Polysaccharide Conjugate Vaccine (Freeze-Dried)
home

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (0.5 mL) contains:
5 μg of each Meningococcal A, C, Y, W, and X polysaccharide individually conjugated to a carrier protein. The serogroup A and X polysaccharides are conjugated to purified tetanus toxoid (TT) and the serogroup C, W, and Y polysaccharides are conjugated to recombinant CRM197 (cross-reactive material 197, a nontoxic mutant of diphtheria toxin) protein

Name of Ingredients Quantity per dose (0.5 mL) after reconstitution
N. meningitidis group A polysaccharide Conjugated to TT 5 μg
N. meningitidis group C polysaccharide Conjugated to CRM197 5 μg
N. meningitidis group Y polysaccharide Conjugated to CRM197 5 μg
N. meningitidis group W polysaccharide Conjugated to CRM197 5 μg
N. meningitidis group X polysaccharide Conjugated to TT 5 μg
TT 7.8 to 33.4 μg
CRM197 11.7 to 50.1 μg
Pharmaceutical Form

MenFive is a freeze-dried formulated vaccine available in two presentations viz. 5-dose vial and single-dose vial. The freeze-dried vaccine is to be reconstituted with provided diluent i.e. 0.9% sodium chloride prior to the administration.

Single-dose vial:

For the preparation of the of MenFive, the single-dose vaccine vial is reconstituted with 0.5 mL of provided diluent i.e. 0.9% sodium chloride. Neither the vaccine nor the diluent contains any preservative.

5-dose vial:

For the preparation of MenFive, the 5-dose vaccine vial is reconstituted with 2.5 mL of provided diluent i.e. 0.9% sodium chloride.

home
Therapeutic Indications

MenFive is indicated for active immunization of individuals aged 9 months - 85 years against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, W, and X.

Posology

MenFive vaccination course consists of a single dose of 0.5 mL.

Method of Administration

MenFive is for intramuscular (IM) injection only, preferably in the deltoid muscle. In children below 5 years of age, the anterolateral aspect of the thigh may be used as alternate site if injection in the deltoid muscle is not feasible.